An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study)

• Published in: Annals of oncology Vol. 24; no. 4; pp. 924 - 930
• Main Authors: Coombes, R.C., Tat, T., Miller, M.L., Reise, J.A., Mansi, J.L., Hadjiminas, D.J., Shousha, S., Elsheikh, S.E., Lam, E. W-F., Horimoto, Y., El-Bahrawy, M., Aboagye, E.O., Contractor, K.B., Shaw, J.A., Walker, R.A., Marconell, M.H., Palmieri, C., Stebbing, J.
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 01.04.2013; Oxford University Press
• Subjects: Adult; Aged; Antineoplastic agents; Biological and medical sciences; biomarker; Biopsy; breast; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Cell Proliferation - drug effects; ErbB Receptors - metabolism; Female; Forkhead Box Protein M1; Forkhead Box Protein O3; Forkhead Transcription Factors - metabolism; Gene Expression Regulation, Neoplastic - drug effects; Gynecology. Andrology. Obstetrics; HER-3; Humans; Ki-67 Antigen - metabolism; Ki67; Lapatinib; Mammary gland diseases; Medical sciences; Middle Aged; Oncogene Protein v-akt - metabolism; Pharmacology. Drug treatments; pre-surgical; Quinazolines - administration & dosage; Receptor, ErbB-2 - genetics; Receptor, ErbB-3 - metabolism; Receptors, Estrogen - metabolism; Tumors; pre-surgical; lapatinib; biomarker; HER-3; Ki67; breast; Antineoplastic agent; Breast disease; erbB2 Gene; Biological marker; Surgery; Lipopolysaccharide; Adult; Female; Mammary gland; Lapatinib; Woman; Protein-tyrosine kinase; Protooncogene; Human; Enzyme; Tyrosine kinase inhibitor; Transferases; Enzyme inhibitor; Breast cancer; Malignant tumor; Human Epidermal growth factor Receptor 2; Human Epidermal growth factor Receptor 3; Mammary gland diseases; Treatment; C-Onc gene; Ki67 antigen; Breast; Early; Cancer

This phase II, open-label, multicentre study aimed to evaluate changes in cell proliferation and biomarkers, as well as efficacy of lapatinib in treatment-naïve patients with HER-2-negative primary breast cancer. Patients received 1500 mg lapatinib for 28–42 days before surgery with repeat biopsies...